The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation: A Randomized, Controlled Trial
Abstract
BACKGROUND: Cytomegalovirus (CMV) is the most prevalent opportunistic infection after lung transplantation. Current strategies do not prevent CMV in most at-risk patients. OBJECTIVE: To determine whether extending prophylaxis with oral valganciclovir from the standard 3 months to 12 months after lung transplantation is efficacious. DESIGN: Randomized, clinical trial. Patients were randomly assigned by a central automated system to treatment or placebo. Patients and investigators were blinded to treatment status. (ClinicalTrials.gov registration number: NCT00227370) SETTING: Multicenter trial involving 11 U.S. lung transplant centers. PATIENTS: 136 lung transplant recipients who completed 3 months of valganciclovir prophylaxis. INTERVENTION: 9 additional months of oral valganciclovir (n = 70) or placebo (n = 66). MEASUREMENTS: The primary end point was freedom from CMV disease (syndrome or tissue-invasive) on an intention-to-treat basis 300 days after randomization. Secondary end points were CMV disease severity, CMV infection, acute rejection, opportunistic infections, ganciclovir resistance, and safety. RESULTS: CMV disease occurred in 32% of the short-course group versus 4% of the extended-course group (P < 0.001). Significant reductions were observed with CMV infection (64% vs. 10%; P < 0.001) and disease severity (110 000 vs. 3200 copies/mL, P = 0.009) with extended treatment. Rates of acute rejection, opportunistic infections, adverse events, CMV UL97 ganciclovir-resistance mutations, and laboratory abnormalities were similar between groups. During the 6 months after study completion, a low incidence of CMV disease was observed in both groups. LIMITATION: Longer-term effects of extended prophylaxis were not assessed. CONCLUSION: In adult lung transplant recipients who have received 3 months of valganciclovir, extending prophylaxis by an additional 9 months significantly reduces CMV infection, disease, and disease severity without increased ganciclovir resistance or toxicity. A beneficial effect with regard to prevention of CMV disease seems to extend at least through 18 months after transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stewart, S., Fishbein, M. C., Snell, G. I., Berry, G. J., Boehler, A., Burke, M. M., Glanville, A., Gould, F. K., Magro, C., Marboe, C. C., et al. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.10.017 · Cited by 2,442
Infection in Organ-Transplant Recipients
Fishman, J. A., & Rubin, R. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806113382407 · Cited by 1,622
Paya, C., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N., & Pescovitz, M. D. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00382.x · Cited by 880
Limaye, A. P., Corey, L., Koelle, D. M., Davis, C. L., & Boeckh, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02607-6 · Cited by 509
Self-citationRisk factors for bronchiolitis obliterans: a systematic review of recent publications
Sharples, L. D., McNeil, K., Stewart, S., & Wallwork, J. (2002) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(01)00360-6 · Cited by 348
Christie, J. D., Edwards, L. B., Aurora, P., Dobbels, F., Kirk, R., Rahmel, A. O., Taylor, D. O., Kucheryavaya, A. Y., & Hertz, M. I. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.07.018 · Cited by 296
Optimization of Quantitative Detection of Cytomegalovirus DNA in Plasma by Real-Time PCR
Boeckh, M., Huang, M., Ferrenberg, J., Stevens-Ayers, T., Stensland, L., Nichols, W. G., & Corey, L. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.3.1142-1148.2004 · Cited by 260
The Indirect Effects of Cytomegalovirus Infection on the Outcome of Organ Transplantation
Rubin, R. H. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420240121038 · Cited by 240
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir
Chou, S. (2008) · Reviews in Medical Virology · doi:10.1002/rmv.574 · Cited by 205
Infections and solid organ transplant rejection: a cause-and-effect relationship?
Cainelli, F., & Vento, S. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00370-5 · Cited by 163
Cited by
Kotton, C. N., Kumar, D., Caliendo, A. M., Huprikar, S., Chou, S., Danziger-Isakov, L., & Humar, A. (2018) · Transplantation · doi:10.1097/tp.0000000000002191 · Cited by 1,152
Infection in Organ Transplantation
Fishman, J. A. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14208 · Cited by 809
Kotton, C. N., Kumar, D., Caliendo, A. M., Åsberg, A., Chou, S., Danziger-Isakov, L., & Humar, A. (2013) · Transplantation · doi:10.1097/tp.0b013e31829df29d · Cited by 758
Razonable, R. R., & Humar, A. (2019) · Clinical Transplantation · doi:10.1111/ctr.13512 · Cited by 753
Cytomegalovirus in Solid Organ Transplantation
Razonable, R. R., & Humar, A. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12103 · Cited by 544
Metadata
- Authors
- Palmer, S. M., Limaye, A. P., Banks, M., Gallup, D., Chapman, J., Lawrence, E. C., Dunitz, J., Milstone, A., Reynolds, J., Yung, G. L., Chan, K. M., Aris, R., Garrity, E., Valentine, V., McCall, J., Chow, S.-C., Davis, R. D., & Avery, R.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2010-06-15
- Volume
- 152
- Issue
- 12
- Pages
- 761-769
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2145871241
- Cited by
- 259
- References
- 14
- FWCI
- 17.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation: A Randomized, Controlled Trial. https://app.cochat.ai/papers/10.7326/0003-4819-152-12-201006150-00003
- The paper
- Palmer, S. M., Limaye, A. P., Banks, M., Gallup, D., Chapman, J., Lawrence, E. C., Dunitz, J., Milstone, A., Reynolds, J., Yung, G. L., Chan, K. M., Aris, R., Garrity, E., Valentine, V., McCall, J., Chow, S.-C., Davis, R. D., & Avery, R. (2010). Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation: A Randomized, Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-152-12-201006150-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.